ReviewCurrent opinion in hematology2017
An update on the diagnosis and treatment of chronic idiopathic neutropenia.
Review in Current opinion in hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 68 citations in OpenAlex.
- Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor.Current opinion in hematology · 2019Trial
- Long-term mutational analysis, clonal metrics, and dynamics in patients with chronic idiopathic neutropenia.HemaSphere · 2026Article
- Drug-induced neutropenia: A comprehensive pharmacovigilance study of the FAERS database.Medicine · 2026Article
- Feline leukemia virus-negative acute lymphoid B-cell aleukemic leukemia in a cat with prolonged survival.The Canadian veterinary journal = La revue veterinaire canadienne · 2026Article
- Isolated Chronic Neutropenia in Adults: Causes, Diagnostic Work-Up, and Management-A Narrative Review.Journal of clinical medicine · 2025Review
- Fournier's gangrene in a woman with chronic neutropenia presenting at 12 weeks of pregnancy: a case report and literature review.Case reports in women's health · 2025Article
- T Cell Repertoire Analysis as a Molecular Signature of the Spectrum of T-LGL Lymphoproliferative Disorders: Tracing the Literature.Current issues in molecular biology · 2025Review
- Article
- Isolated Severe Neutropenia in Adults, Evaluation of Underlying Causes and Outcomes, Real-World Data Collected over a 5-Year Period in a Tertiary Referral Hospital.Medicina (Kaunas, Lithuania) · 2024Article
- Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases.Pharmaceutics · 2024Review
- Screening for ELANE, HAX1 and GFI1 gene mutations in children with neutropenia and clinical characterization of two novel mutations in ELANE gene.BMC pediatrics · 2023Article
- Telomerase RNA-based aptamers restore defective myelopoiesis in congenital neutropenic syndromes.Nature communications · 2023Article
- Severe congenital neutropenia mimicking chronic idiopathic neutropenia: a case report.Journal of Yeungnam medical science · 2023Article
- Prevalence of neutropenia in US residents: a population based analysis of NHANES 2011-2018.BMC public health · 2023Article
- Article
- Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor.Blood advances · 2022Article
- Transient thrombocytopenia in a cat following G-CSF treatment.Veterinary medicine and science · 2022Article
- Article
- Diagnosis and therapeutic decision-making for the neutropenic patient.Hematology. American Society of Hematology. Education Program · 2021Article
- Two Cases of Autoimmune Neutropenia Complicated with Other Lineages of Autoimmune Cytopenia, Successfully Treated with Prednisolone.Internal medicine (Tokyo, Japan) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewNeutropenia lasting for at least for 3 months and not attributable to drugs or a specific genetic, infectious, inflammatory, autoimmune or malignant cause is called chronic idiopathic neutropenia (CIN). CIN and autoimmune neutropenia (AIN) are very similar and overlapping conditions. The clinical consequences depend upon the severity of neutropenia, but it is not considered a premalignant condition. RECENT
findingsLong-term observational studies in children indicate that the disease often lasts for 3-5 years in children, then spontaneously remits, but it rarely remits in adult cases. The value of antineutrophil antibody testing in both children and adults is uncertain. Most recent data suggest that CIN and AIN are immune-mediated diseases, but there are no new clinical or genetic tests to aid in diagnosis. Treatment with granulocyte colony stimulating factor (G-CSF) is effective to increase blood neutrophils in almost all cases; this treatment is reserved, however, for patients with both neutropenia and evidence of recurrent fevers, inflammatory symptoms and infections. There is little or no evidence to indicate that G-CSF treatment predisposes to myeloid malignancies in this population. SUMMARY: It is important to recognize CIN and AIN, the most common causes of chronic neutropenia in both children and adults. If the neutropenia is not severe, that is more than 0.5 × 10/l, most patients can be observed and not treated prophylactically with antibiotics or a growth factor. When neutropenia is severe, treatment with G-CSF is often beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.